Sowunmi Akintunde, Balogun Sulayman T, Gbotosho Grace O, Happi Christian T
Department of Pharmacology & Therapeutics and Institute for Medical Research and Training, University of Ibadan, Ibadan, Nigeria.
Malar J. 2008 Sep 2;7:169. doi: 10.1186/1475-2875-7-169.
Amodiaquine is frequently used as a partner drug in combination therapy or in some setting as monotherapy, but little is known about its effects on gametocyte production and sex ratio and its potential influence on transmission in Africa. The effects of amodiaquine on sexual stage parasites and gametocyte sex ratio, and the factors associated with a male-biased sex ratio were evaluated in 612 children with uncomplicated Plasmodium falciparum malaria who were treated with amodiaquine during the period 2000 - 2006 in an endemic area.
Clinical, parasitological and laboratory parameters were evaluated before treatment and during follow-up for 28-42 days, and according to standard methods. Gametocyte sex ratio was defined as the proportion of peripheral gametocytes that are male.
Clinical recovery from illness occurred in all children. Gametocytaemia was detected in 66 patients (11%) before treatment and in another 56 patients (9%) after treatment. Gametocyte densities were significantly higher by days 3-7 following treatment compared with pre-treatment (P < 0.0001). Overall, mean gametocyte sex ratio increased significantly during follow-up and over the study periods from 2000-2006 (P < 0.001 in both cases), but was female-biased at enrolment throughout the study periods. Absence of fever, a haematocrit < 25%, asexual parasitaemia > 20,000/microL, gametocytaemia < 18/microL, and enrolment in 2006 were associated with a male-biased sex ratio pre-treatment. Anaemia and high parasitaemia were independent predictors of gametocyte maleness 7 days post treatment.
Amodiaquine may significantly increase gametocyte carriage, density and sex ratio, and may potentially influence transmission. It is possible that anaemia could have contributed to the increased sex ratio. These findings may have implications for malaria control efforts in Africa.
阿莫地喹常用于联合治疗中的辅助用药,或在某些情况下作为单一疗法使用,但在非洲,其对配子体产生、性别比例的影响以及对传播的潜在影响却知之甚少。2000年至2006年期间,在一个疟疾流行地区,对612例患单纯性恶性疟原虫疟疾且接受阿莫地喹治疗的儿童,评估了阿莫地喹对有性期寄生虫和配子体性别比例的影响,以及与雄性偏向性别比例相关的因素。
按照标准方法,在治疗前及随访28 - 42天期间评估临床、寄生虫学和实验室参数。配子体性别比例定义为外周血中雄性配子体的比例。
所有儿童均从疾病中临床康复。治疗前在66例患者(11%)中检测到配子血症,治疗后在另外56例患者(9%)中检测到。与治疗前相比,治疗后第3 - 7天配子体密度显著更高(P < 0.0001)。总体而言,在随访期间以及2000年至2006年的研究期间,平均配子体性别比例均显著增加(两种情况P均 < 0.001),但在整个研究期间入组时均以雌性为主。无发热、血细胞比容 < 25%、无性疟原虫血症 > 20,000/微升、配子血症 < 18/微升以及2006年入组与治疗前雄性偏向性别比例相关。贫血和高疟原虫血症是治疗后7天配子体雄性化的独立预测因素。
阿莫地喹可能显著增加配子体携带率、密度和性别比例,并可能潜在影响传播。贫血可能导致了性别比例增加。这些发现可能对非洲的疟疾控制工作产生影响。